PTHS
MaterialsChannel Therapeutics Corporation
Live · AMEX · May 9, Close
What's Moving PTHS Today?
No stock-specific AI insight has been generated for PTHS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
PTHS News
20 articles- Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026Yahoo Finance·May 1, 2026
- Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumYahoo Finance·Apr 14, 2026
- Pelthos Therapeutics Announces CFO TransitionYahoo Finance·Apr 10, 2026
- Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye PainYahoo Finance·Mar 31, 2026
- Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth InterviewMarketbeat·Mar 29, 2026
- Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...Yahoo Finance·Mar 19, 2026
- Pelthos Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 19, 2026
- Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 19, 2026
- Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 19, 2026
- Pelthos Therapeutics to Present at 38th Annual ROTH ConferenceYahoo Finance·Mar 12, 2026
- Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026Yahoo Finance·Mar 9, 2026
- Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 23, 2026
- Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos TherapeuticsYahoo Finance·Jan 15, 2026
- Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology FinanceYahoo Finance·Jan 13, 2026
- Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head LiceYahoo Finance·Jan 5, 2026
- Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew EinhornYahoo Finance·Dec 23, 2025
- Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%Yahoo Finance·Dec 4, 2025
- Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceYahoo Finance·Dec 2, 2025
- Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial ResultsYahoo Finance·Nov 13, 2025
- LGND: Target Up On Improved Growth OutlookYahoo Finance·Nov 10, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Channel Therapeutics Corporation
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.